Please login to the form below

Not currently logged in
Email:
Password:

cost

This page shows the latest cost news and features for those working in and with pharma, biotech and healthcare.

Novartis sees five new $1bn-plus launches in next two years

Novartis sees five new $1bn-plus launches in next two years

He said the price would be far lower than that, but would be set at “a fraction” of the current cost of care – which is in the $4m-$5m range over ... Analysts think the eventual price will be close to $2m, while the influential Institute for

Latest news

More from news
Approximately 9 fully matching, plus 2,690 partially matching documents found.

Latest Intelligence

  • It’s not the end of the world, is it? It’s not the end of the world, is it?

    not claim to offer value, cost-effectiveness or some other paraphrasing of the value-based mantra. ... our industry (and indeed, any industry) offers is not the best possible value for money when considered from a strictly full-cost for full-benefit

  • Is anybody listening? Is anybody listening?

    and facilitate both direct and indirect healthcare cost savings,” says Craig. ... The potential rewards are significant; peer-to-peer engagement improves outcomes and reduces the cost and burden of disease.

  • The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt

    And, to me, there are three. The first is that the government has threatened the industry during every recent PPRS negotiation with a reduction in the standard NICE cost-effectiveness threshold. ... the government dictates, or forcing all companies into

  • The first, my last, my everything The first, my last, my everything

    Well-designed solutions, particularly for complex high-cost conditions, are going beyond traditional ‘adherence’ tools and instead providing personalised programmes that add value to the patient experience.

  • The Orkambi row explained The Orkambi row explained

    If England were to pay this price for the approximately 2, 834 people who are eligible, it would cost around £295m, which would make it one of the country’s biggest ... April 2016: NICE’s initial rejection of Orkambi despite evidence of its efficacy,

More from intelligence
Approximately 2 fully matching, plus 430 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 326 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics